58 results about "Recombinant vaccines" patented technology

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The present invention relates to the field of biomedical technologies, and discloses a long-acting and stable recombinant RSV vaccine based on glycan modification and phase change materials. The vaccine comprises the following components in parts by mass: RSV F protein modified with dynamic glycans: 1 part; multi-stage phase change materials: 3-5 parts, and the multi-stage phase change materials are composed of polyethylene glycol-stearate and lauric acid-cholesterol complex, wherein the mass ratio of polyethylene glycol-stearate to lauric acid-cholesterol is 2-3:1; TLR9 agonist: 0.05-0.15 part; STING agonist: 0.02-0.08 part; amphiphilic block copolymer PLGA-PEG-PLL: 0.5-1.5 parts. The present invention solves the problems of easy inactivation, poor targeting and insufficient immunogenicity of traditional vaccines, is applicable to the prevention and treatment of viral infectious diseases, and has the application potential for large-scale production.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

The invention relates to a novel immunogenic composition for preventing and treating pseudomonas aeruginosa infection, a fusion protein, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion molecular architecture, which comprises a fusion protein A coded by three genes of EF-Tu, DnaK and EF-G, or a fusion protein B coded by two genes of PcrV and PilA, or a combination of the fusion protein A and the fusion protein B, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The invention finds that the novel fusion molecule has good immunogenicity, can provide an effective immune protection effect, remarkably inhibits colonization of pseudomonas aeruginosa, and has a wide application prospect.

The application provides a standard plasmid for detecting the copy number of exogenous genes of a recombinant CVA10 vaccine, and a preparation method and application thereof. The standard plasmid of the application comprises an endogenous gene MOX fragment SEQ ID No. 1, an exogenous gene P1 fragment SEQ ID No. 2 and an exogenous gene 3CD fragment SEQ ID No. 3 which are connected in series in a cloning vector. The application constructs the standard plasmid, adopts Taqman probe-fluorescence quantitative PCR method, and simply, quickly, absolutely quantitatively and accurately analyzes the copy number of inserted exogenous genes, so that the detection time of the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine is effectively shortened, repeated operation is facilitated, and the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine based on the Hansenula platform and the verification of the genetic stability of the exogenous genes of the recombinant CVA10 vaccine have a wide application prospect.

The application discloses a CMV virus-like particle for producing a VLP recombinant vaccine and a preparation method thereof, the CMV virus-like particle is obtained by cloning a C-terminal G4SLPETG modified plant virus cucumber mosaic virus CMV capsid gene into a prokaryotic expression vector to obtain a recombinant expression vector, the recombinant expression vector is transfected into E. coli BL21 (DE3), and expression is obtained through the recombinant E. coli BL21 (DE3); and the amino acid sequence of the C-terminal G4SLPETG modified CMV is SEQ ID NO. 1. Test proves that the recombinant strain constructed by the application is stable to expression of an exogenous protein. The recombinant protein expressed by the application is used for preparing a virus-like particle for antigen coupling, the coupling efficiency is high, the antigen purity is high, the safety is good, the virus-like particle is not pathogenic to mice and other animals, and the safety evaluation is easy.

The present application relates to the fusion protein, immunogenic composition, recombinant vaccine and application for preventing acinetobacter baumannii infection, etc. The present application screens and obtains four groups of antigen combination fusion protein mRNA vaccines of AdeK-LolB, Omp22-HphA, Omp22-LolB and CsuE-CsuAB, which show excellent effects in the mouse acinetobacter baumannii infection model. Compared with the nucleic acid vaccine encoded by the Omp22-Omp38 fusion protein known in the prior art and having excellent effects itself, the nucleic acid vaccine has better immunization effects and protective effects for preventing acinetobacter baumannii infection in reducing acinetobacter baumannii colonization and reducing the degree of lesions caused by infection, and has a wide application prospect.

This invention relates to the field of vaccine preparation technology, specifically disclosing a VSV-based HTNV vaccine, its preparation method, and its application. The method involves constructing a recombinant plasmid by inserting the nucleotide sequence of the HTNV envelope glycoprotein into the recombinant VSV vector plasmid, followed by packaging and processing to obtain an immunogenic HTNV recombinant VSV vaccine. The HTNV vaccine prepared by this invention provides a novel candidate vaccine for the prevention and treatment of hemorrhagic fever with renal syndrome.

The present invention relates to a viral vector capable of generating a cellular immune response against a spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterized in that the viral vector is a Newcastle disease virus (NDV) comprising a nucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 14 and an exogenous nucleotide sequence encoding antigenic sites of SARS-CoV-2, wherein the exogenous nucleotide sequence comprises a sequence having at least 95% sequence identity with a sequence that translates into the amino acid sequence of SEQ ID NO: 11, wherein the exogenous nucleotide sequence comprises an ectodomain of a SARS-CoV-2 S protein fused with a transmembrane domain and a cytoplasmic domain of an NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to alanine and amino acids 817, 892, 899, 942,986 and 987 of the ectodomain of the S protein of SEQ ID NO: 11 are prolines, such that the viral vector and antigenic sites are stable after at least 3 consecutive passages in chicken embryo.

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

The invention belongs to the technical field of biology, and relates to an antigen optimization method based on H9N2 subtype avian influenza virus hemagglutinin protein epitope modification. According to the invention, immune response effects of different key antigen regions of H9N2 subtype AIV HA protein are systematically evaluated through monoclonal antibody scheduling and antigen mapping analysis, and antigen regions A (sequences of S145D, K149T, D153G and H9 HA with signal peptides) having an optimization effect on current recombinant viruses are screened out. Experimental results show that the modified recombinant vaccine candidate strain R118-A has broad-spectrum neutralization titer and a protection effect on the group 1 virus strain and the group 2 virus strain, and the recombinant vaccine candidate strain R118-A has the broad-spectrum neutralization titer and the protection effect on the group 1 virus strain and the group 2 virus strain.

The invention relates to a fusion protein for preventing pathogenic enterococcus infection, an immunogenic composition, a recombinant vaccine, application of the fusion protein, the immunogenic composition and the recombinant vaccine and the like. According to the invention, HlyC / CorC transporter antigens of enterococcus faecium and enterococcus faecalis are selected to construct a fusion protein A, and elongation factor Tu antigens and 50S ribosomal protein L7 / L12 (50S ribosomal protein L7 / L12, rplL) antigens of the enterococcus faecium and the enterococcus faecalis are selected to construct a fusion protein B. According to the present invention, the fusion protein A and the fusion protein B are selected, the vaccine based on the two fusion proteins can significantly weaken tissue infection caused by enterococcus faecium and enterococcus faecalis, has good immunogenicity, plays effective prevention and immune protection roles, can efficiently prevent pathogenic enterococcus infection, and has wide application prospects.

Described is a recombinant vaccine against porcine epidemic diarrhea (PED) comprising a viral vector having inserted therein an exogenous nucleotide sequence encoding an antigen site of PED virus type 2, and a pharmaceutically acceptable solvent, adjuvant and / or excipient wherein the vaccine is suitable for generating an immune response in a porcine body, the vaccine does not need to be combined with other vaccines or forms of PED virus type 2.

The present invention discloses a recombinant herpes simplex virus type I vaccine and its application, belonging to the field of vaccine technology. Specifically, it relates to a fusion protein composed of an antigen molecule gD1, a human immunoglobulin antibody Fc domain and a human IgG1 hinge region fragment, wherein the amino acid sequence of the antigen molecule gD1 is shown in SEQ ID NO.6, and a recombinant vaccine is constructed. The recombinant vaccine of the present invention fuses viral antigens, immunoglobulin heavy chain Fc domain and human IgG1 hinge region fragment, has a better ability to bind to receptors on the surface of antigen-presenting cells, and can activate specific CD4 + T and CD8 + T cells, producing high titer antibody titers and specific cellular immunity. This vaccine can prevent infection and / or reinfection with herpes simplex virus type 1.

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and / or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

The application belongs to the technical field of biotechnology, and provides a porcine deltacoronavirus recombinant DNA vaccine, a construction method and application thereof, the porcine deltacoronavirus recombinant DNA vaccine comprising a porcine deltacoronavirus NTD antigen gene or a porcine deltacoronavirus RBD antigen gene; wherein the nucleotide sequence of the porcine deltacoronavirus NTD antigen gene is shown as SEQ ID NO. 1, and the nucleotide sequence of the porcine deltacoronavirus RBD antigen gene is shown as SEQ ID NO. 2. The application firstly fuses the immunogenic gene fragments NTD and RBD of PDCoV with IgG1 Fc fragments respectively, constructs a recombinant DNA vaccine, and evaluates the safety, immunogenicity and protective efficacy of the recombinant DNA vaccine through experiments, and verifies that the PDCoV recombinant DNA vaccine has good effects in preventing porcine deltacoronavirus infection.

This invention relates to fusion proteins, immunogenic compositions, recombinant vaccines, and applications for the prevention of Toxoplasma gondii infection. From a reverse vaccinology perspective, this invention, through screening and optimization, provides a novel fusion molecular structure comprising a fusion protein encoded by two genes: the SPATR antigen and the MIC2 antigen. This fusion protein can be successfully translated, correctly folded, and secreted extracellularly in eukaryotic cells. Based on the aforementioned SPATR-MIC2 fusion mRNA vaccine, a 100% protective effect against Toxoplasma gondii infection can be achieved in a mouse model of Toxoplasma gondii infection, significantly superior to the inactivated vaccine group. The fusion protein of this invention exhibits good immunogenicity and can provide effective immune protection against Toxoplasma gondii infection, showing broad application prospects.

The present disclosure provides a recombinant protein comprising a signal peptide, an S1 domain of a porcine epidemic diarrhea virus S protein, and a multimerization sequence. The present disclosure also provides a recombinant vaccine prepared from the recombinant protein, which has the advantages of higher safety, no reverse toxicity, stimulation of the body to produce an effective neutralizing antibody concentration, and batch production consistency.

The application belongs to the technical field of biology, and particularly relates to a grass carp reovirus (GCRV-Ⅱ type) subunit recombinant vaccine, a preparation method and application. 274‑367 , VP5 105‑336 , NS38 143‑338 sequence fragments, and the three sequence fragments are recombined and expressed in a prokaryotic expression vector to prepare the subunit recombinant vaccine. The recombinant vaccine has high safety, strong activity and broad spectrum, and has good application potential.

The invention discloses a preparation method and application of PD-L1mRNA targeting deoxyoligonucleotide carrying a CpG sequence, two PD-L1mRNA targeting ASO (named as P4 and P9) are designed and screened by taking a human PD-L1mRNA coding region conserved sequence and a mouse PD-L1mRNA coding region conserved sequence as a target region; cpG sequences are added to 3'ends of P4 and P9, and whether RCP4 and RCP9 can play an adjuvant role in improving the antibody level or inhibiting tumor growth in recombinant HBsAg vaccines and anti-kidney cancer vaccines or not is researched through in-vivo experiments. According to the invention, PD-L1mRNA targeting ASOs carrying a CpG sequence is innovatively designed as a novel adjuvant, the ASOs are used for inhibiting a PD-1 / PD-L1 signal channel and activating a TLR9 signal channel, meanwhile, an innate immune system and an adaptive immune system are activated, early activation and late response of CD8 < + > T cells are promoted, and the CD8 < + > T cells are effectively inhibited. Finally, the purpose of enhancing the immune effect of the antiviral vaccine and the immune effect of the anti-tumor vaccine is achieved. The implementation of the invention not only can provide a strategy for the development of novel vaccine adjuvants, but also lays a foundation for the development of effective antiviral vaccines and anti-tumor vaccines.

Avian necrotic enteritis (NE) is a complex and multifactorial enteric disease of commercial chickens and turkeys that has major economic consequences on the poultry industry worldwide. There is thus a need for improved and efficient vaccines for the prevention of diseases associated to pathogenic Clostridium perfringens in the poultry industry. The present application discloses immunogenic polypeptides unique to pathogenic strains of Clostridium perfringens which causes avian NE, as well as vaccine compositions comprising one or more of the immunogenic polypeptides, immunogenic fragments thereof, or nucleic acids encoding such immunogenic polypeptides and fragments. Methods and uses of the vaccine compositions for inducing or eliciting an immune response against Clostridium perfringens, for preventing or treating infection by Clostridium perfringens, and / or for preventing or treating avian NE in an animal, such as a poultry, are also disclosed.